GlobeNewswire·Mar 6, 2026, 7:00 AM ET

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

JADE101 Phase 1 healthy volunteer interim data expected in Q2 2026, with a Phase 2 trial in IgA nephropathy patients starting mid-2026 \& preliminary data anticipated in 2027.
JADE201 is expected to enter a first-in-human clinical trial in rheumatoid arthritis patients in Q2 2026, with interim data anticipated in 2027.
Third candidate JADE301 has been nominated, with a Phase 1 clinical trial expected to commence in the first half of 2027.
Cash, cash equivalents, \& investments totaled $336.2 million as of December 31, 2025, providing a runway into the first half of 2028.
Jade completed two private placement financings in Q4 2025 resulting in gross proceeds of approximately $180 million.
Research \& development expenses were $93.1 million for the full year 2025, compared to $31.2 million for the period from inception to December 31, 2024.
General \& administrative expenses were $20.4 million for the full year 2025, compared to $4.3 million for the period from inception to December 31, 2024.
Net loss for the full year 2025 was $127.4 million, compared to $47.0 million for the period from inception to December 31, 2024.
Shares outstanding as of December 31, 2025, were approximately 70.7 million common stock \& equivalents.